1-Tert-butyl-2,3-difluoro-4-methoxybenzene

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-Tert-butyl-2,3-difluoro-4-methoxybenzene
• 英文别名: 1-tert-butyl-2,3-difluoro-4-methoxybenzene
• 化学式: C₁₁H₁₄F₂O
• 分子量: 200.22
• InChiKey: CJFXCJWHEOHXSZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• NOVEL SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF
  申请人：SANOFI

  公开号：US20180079720A1

  公开（公告）日：2018-03-22

  Compounds of formula (I): wherein R1 and R2 represent hydrogen or deuterium atoms; R3 represents a hydrogen atom or a —COOH, a —OH or a —OPO(OH) 2 group; R4 represents a hydrogen atom or a fluorine atom; R5 represents a hydrogen atom or a —OH group; wherein at least one of R3 or R5 is different from a hydrogen atom; when R3 represents a —COOH, —OH or —OPO(OH) 2 group, then R5 represents a hydrogen atom; when R5 represents a —OH group, then R3 and R4 represent hydrogen atoms; and R6 is selected from an optionally substituted phenyl, heteroaryl, cycloalkyl and heterocycloalkyl group; and the preparation and the therapeutic uses of the compounds of formula (I) as inhibitors and degraders of estrogen receptors, useful especially in the treatment of cancer.

  化合物的式子为(I):其中R1和R2代表氢或氘原子；R3代表氢原子或—COOH，—OH或—OPO(OH)2基团；R4代表氢原子或氟原子；R5代表氢原子或—OH基团；其中至少一个R3或R5不同于氢原子；当R3代表—COOH，—OH或—OPO(OH)2基团时，R5代表氢原子；当R5代表—OH基团时，R3和R4代表氢原子；R6从可选取的取代苯基，杂环芳基，环烷基和杂环烷基群中选择；化合物的制备和治疗用途为公式(I)的抑制剂和降解剂，特别适用于癌症治疗。
• PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE2 INHIBITORS AND/OR CYP3A4 INHIBITORS
  申请人：Helal Christopher John

  公开号：US20140080806A1

  公开（公告）日：2014-03-20

  The present invention provides, inter alia, compounds of Formula (I) and pharmaceutically acceptable salts thereof, to processes for the preparation of, intermediates used in the preparation of and compositions containing such compounds and the uses of such compounds as a method for the treatment of a disease or condition selected from the group consisting of central nervous system disorders, cognitive disorders, schizophrenia, dementia and other disorders in a mammal. The present invention further provides compounds of Formula (Id) and pharmaceutically acceptable salts thereof as CYP3A4 selective inhibitors.

  本发明提供了公式(I)的化合物及其药学上可接受的盐，以及制备这些化合物所使用的中间体、含有这些化合物的组合物和将这些化合物用作哺乳动物中治疗中枢神经系统疾病、认知障碍、精神分裂症、痴呆和其他疾病的方法。本发明还提供了公式(Id)的化合物及其药学上可接受的盐作为CYP3A4选择性抑制剂。
• Substituted 6,7-dihydro-5H-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof
  申请人：SANOFI

  公开号：US10570090B2

  公开（公告）日：2020-02-25

  Compounds of formula (I): wherein R1 and R2 represent hydrogen or deuterium atoms; R3 represents a hydrogen atom or a —COOH, a —OH or a —OPO(OH)2 group; R4 represents a hydrogen atom or a fluorine atom; R5 represents a hydrogen atom or a —OH group; wherein at least one of R3 or R5 is different from a hydrogen atom; when R3 represents a —COOH, —OH or —OPO(OH)2 group, then R5 represents a hydrogen atom; when R5 represents a —OH group, then R3 and R4 represent hydrogen atoms; and R6 is selected from an optionally substituted phenyl, heteroaryl, cycloalkyl and heterocycloalkyl group; and the preparation and the therapeutic uses of the compounds of formula (I) as inhibitors and degraders of estrogen receptors, useful especially in the treatment of cancer.

  式(I)化合物： 其中 R1 和 R2 代表氢原子或氘原子；R3 代表氢原子或-COOH、-OH 或-OPO(OH)2 基团；R4 代表氢原子或氟原子；R5 代表氢原子或-OH 基团；其中 R3 或 R5 中至少有一个不同于氢原子；当 R3 代表-COOH、-OH 或-OPO(OH)2 基团时，则 R5 代表氢原子；当 R5 代表-OH 基团时，则 R3 和 R4 代表氢原子；以及 R6 选自任选取代的苯基、杂芳基、环烷基和杂环烷基； 以及式（I）化合物作为雌激素受体抑制剂和降解剂的制备和治疗用途，特别是在癌症治疗中的用途。
• FUSED THIOPHENE DERIVATIVES AND THEIR USES
  申请人：ENYO PHARMA

  公开号：US20200369682A1

  公开（公告）日：2020-11-26

  The present invention relates to a new class of fused thiophene derivatives and their uses for treating diseases such as infection, cancer, metabolic diseases, cardiovascular diseases, iron storage disorders and inflammatory disorders.
• PYRIDINONE AND PYRIMIDINONE PHOSPHATES AND BORONATES USEFUL AS ANTIBACTERIAL AGENTS
  申请人：Pfizer Inc.

  公开号：US20210017206A1

  公开（公告）日：2021-01-21

  The present invention is directed to new pyridinone or pyrimidinone hydroxamic acid phosphates of Formula (1) and boronates of Formula (2), stereoisomers thereof; wherein Q is selected from the group consisting of —P(O)(OH) 2 , —P(O)(OH)(O − M + ), —P(O)(O − M + ) 2 and —P(O)(O − ) 2 M 2+ ; M + at each occurrence is a pharmaceutically acceptable monovalent cation; and M 2+ is a pharmaceutically acceptable divalent cation; X is CH or N; and Z is as defined herein; and their use as LpxC inhibitors and, more specifically, their use to treat bacterial infections.